PharmaMar Wins Taiwan First-Line Maintenance Nod for Zepzelca in SCLC

Pharma Mar SA ( (ES:PHM) ) has provided an announcement.

PharmaMar has secured approval from Taiwan’s Food and Drug Administration for its lung cancer drug Zepzelca, in combination with atezolizumab, as a first-line maintenance therapy for adults with advanced small cell lung cancer. This positions the company to deepen its presence in oncology markets where maintenance strategies are gaining importance.

The Taiwan decision adds to a string of recent first-line maintenance approvals for the same combination in the United Arab Emirates, Oman, Israel, Uruguay, Ecuador, Paraguay and Peru, alongside earlier greenlights in the United States and Switzerland. With a marketing application under review at the European Medicines Agency and 22 existing approvals worldwide as a second-line monotherapy, Zepzelca’s expanding label underscores PharmaMar’s growing footprint in global cancer care.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR89.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

More about Pharma Mar SA

PharmaMar S.A. (MSE: PHM) is a Spanish biopharmaceutical company with four decades of experience focused on oncology. Its portfolio includes the anticancer drug Zepzelca (lurbinectedin), which is used globally in the treatment of small cell lung cancer and has secured multiple regulatory approvals as a second-line monotherapy.

Average Trading Volume: 40,789

Technical Sentiment Signal: Strong Buy

Current Market Cap: €1.55B

For a thorough assessment of PHM stock, go to TipRanks’ Stock Analysis page.